Superworth

PAVmed revenue PAVM

Sales by quarter and over the last twelve months, from 2021.

Last 12 months, to Jun 30, 2026
$112K
Latest quarter, Q2 FY26
$33K
+450% on a year earlier
Fiscal year 2025
$71K
−98% on the year before

PAVmed's revenue was $112K over the twelve months to Jun 30, 2026, down 89% on a year earlier.

In its latest quarter, Q2 FY26, it was $33K, up 450% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$71K−98%
FY2024$3M+22%
FY2023$2.5M+550%
FY2022$377Kn/a
FY2021n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$33K+450%$112K
Q1 FY26$22K+175%$85K
Q4 FY25$52K+420%$71K
Q3 FY25$5K−99%$29K
Q2 FY25$6K−99%$1M
Q1 FY25$8K−99%$2M
Q4 FY24$10K−99%$3M
Q3 FY24$996K+26%$4M
Q2 FY24$979K+490%$3.8M
Q1 FY24$1M+126%$3M
Q4 FY23$1M+837%$2.5M
Q3 FY23$791K+941%$1.5M

Against its peers

Companies in Medical - Instruments & Supplies nearest PAVmed's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
PAVMPAVmed$112K−89% a year
NEPHNephros$20.7M+24% a year
APTAlpha Pro Tech$61.9M+6% a year
KEQUKewaunee Scientific$277.2M+5% a year
Peer median$61.9M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on PAVmed

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.